Penumbra Reports 14.9% Revenue Growth in Second Quarter 2026
The thrombectomy specialist posted revenue of $390 million for the quarter ended June 30, marking double-digit year-over-year growth.
Strong Quarter for Thrombectomy Leader
Penumbra, Inc. (NYSE: PEN) reported second quarter 2026 revenue of $390.0 million on July 30, representing a 14.9% increase compared to the same period in the prior year. The Alameda, California-based company, which describes itself as the world's leading thrombectomy company, released its quarterly financial results through company IR channels and SEC filings.
The medical device manufacturer, which focuses on innovative therapies for vascular and neurovascular conditions, maintains a market capitalization of approximately $13 billion. Shares last closed at $321.19.
Recent Corporate Activity
Recent insider transactions at Penumbra have shown mixed activity, according to MarginX data. Director Adam Elsesser executed a gift transaction involving 77,000 shares, while Harpreet Grewal sold 100 shares. Additionally, Lambert Shiu had 150 shares withheld for tax purposes.
These transactions represent routine corporate governance activities and are disclosed in compliance with SEC regulations.
Looking Ahead
Penumbra is expected to report its third quarter 2026 financial results on November 3, 2026, according to MarginX data. The announcement will provide investors with insight into whether the company can sustain its double-digit revenue growth trajectory through the second half of the year.
The broader macroeconomic environment will also be in focus as the Federal Reserve prepares for upcoming policy decisions. The FOMC is scheduled to announce its rate decision along with economic projections on September 16, followed by another rate decision on October 28. These monetary policy developments could influence healthcare sector valuations and capital deployment strategies across the medical device industry.
Penumbra's performance comes amid continued demand for minimally invasive thrombectomy solutions, a market segment that has seen steady growth as healthcare providers increasingly adopt catheter-based treatments for stroke and other vascular conditions.
This article was generated by MarginX from public news on 2026-07-30. It is not investment advice.